文献速递其他结缔组织病

西班牙RESCLE登记研究中系统性硬化症左心室舒张功能障碍的临床、免疫学及生存差异

Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry.
PubMed 文献 · Semin Arthritis Rheum · 2022-05-28

基于西班牙多中心硬皮病登记(RESCLE)1517例患者的观察性研究显示,21.0%存在左心室舒张功能障碍(LVDD)。LVDD与诊断时年龄较大、病程较长、毛细血管扩张及钙通道阻滞剂治疗相关,与ACE抑制剂使用呈负相关;LVDD患者死亡率升高(23.8% vs 17.4%,p=0.010),但LVDD并非死亡的独立危险因素。

要点

  • 1517例系统性硬化症患者中319例(21.0%)存在左心室舒张功能障碍。
  • LVDD与诊断时年龄较大、病程较长、毛细血管扩张及钙通道阻滞剂治疗相关,与ACE抑制剂使用呈负相关。
  • LVDD患者死亡率升高(23.8% vs 17.4%,p=0.010),但LVDD并非死亡的独立危险因素。

核心结论

  • LVDD在系统性硬化症患者中相对常见,与较差的预后、诊断时年龄较大、病程较长、毛细血管扩张及血管扩张剂治疗相关。

研究设计与样本

  • 利用西班牙多中心硬皮病登记(RESCLE)数据开展的观察性研究,共纳入1517例系统性硬化症患者。

主要发现

  • 1517例患者中319例(21.0%)存在LVDD。
  • 局限型皮肤系统性硬化症亚组与LVDD相关(14.7% vs 10.6%,p=0.048),而弥漫型皮肤系统性硬化症在无LVDD组更常见(16.0% vs 21.2%,p=0.041)。
  • 多变量分析显示LVDD与诊断系统性硬化症时年龄较大(OR 1.05;95%CI 1.04至1.06)、诊断后时间较长(OR 1.04;95%CI 1.03至1.06)、存在毛细血管扩张(OR 1.42;95%CI 1.08至1.88)、使用钙通道阻滞剂(OR 1.51;95%CI 1.16至1.96)相关,与使用血管紧张素转换酶抑制剂呈负相关(OR 0.59;95%CI 0.44至0.80)。
  • LVDD患者死亡率升高(23.8% vs 17.4%,p=0.010),自首次系统性硬化症症状起生存期缩短(p=0.040),但LVDD并非死亡的独立危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Left ventricular diastolic dysfunction (LVDD) remains poorly studied in Systemic Sclerosis (SSc). To determine the prevalence and to define factors associated with LVDD and survival in a large cohort of patients with SSc. METHODS: An observational study was conducted with data from the multicentre Spanish Scleroderma Registry (RESCLE) to identify factors associated with LVDD and estimate survival. RESULTS: Out of 1517 patients, 319 (21.0%) had LVDD. The subset of sine scleroderma SSc was associated to LVDD (14.7% vs. 10.6%, p =0.048), whilst diffuse cutaneous SSc was more prevalent in non-LVDD (16.0 % vs. 21.2%, p =0.041). Multivariable analysis identified that LVDD was associated with older age at diagnosis of SSc (OR 1.05; 95% CI 1.04 to 1.06), longer time from diagnosis (OR 1.04; 95% CI 1.03 to 1.06), presence of telangiectasia (OR 1.42; 95% CI 1.08 to 1.88), treatment with calcium channel blockers (CCB) (OR 1.51; 95% CI 1.16 to 1.96), and inversely related to angiotensin-converting-enzyme inhibitors (ACEi) use (OR 0.59; 95% CI 0.44 to 0.80). SSc patients with LVDD had increased mortality (23.8 vs. 17.4%, p =0.010) and shortened survival from the first SSc symptom (p =0.040), even though it was not found to be an independent risk factor for death. CONCLUSIONS: LVDD is relatively common in SSc patients, and it is associated with worst prognosis, older age, longer time from diagnosis of SSc, presence of telangiectasia and vasodilator treatment.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. González García A, Fabregate M, Manzano L, et al. Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry. Semin Arthritis Rheum. 2022. PMID: 35691226. doi:10.1016/j.semarthrit.2022.152033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。